Mutually exclusive mutations occur early in the tumor in almost all cases, with a mutation frequency of 49% in GNA11. Driver mutations in the Gα proteins GNA11 activate the MAP kinase and YAP/TAZ oncogenic signaling pathways in UVM69. Here, GNA11 is linked to neoplasm.